Collegium Pharmaceutical Enters Material Definitive Agreement
Ticker: COLL · Form: 8-K · Filed: Apr 29, 2024 · CIK: 1267565
| Field | Detail |
|---|---|
| Company | Collegium Pharmaceutical, Inc (COLL) |
| Form Type | 8-K |
| Filed Date | Apr 29, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement
TL;DR
Collegium Pharma just signed a big deal, details TBD.
AI Summary
On April 26, 2024, Collegium Pharmaceutical, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such as the counterparty or financial terms, but indicates it is a significant event for the company.
Why It Matters
This filing signifies a potentially significant development for Collegium Pharmaceutical, Inc., which could impact its business operations, strategic direction, or financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty and potential risk.
Key Players & Entities
- Collegium Pharmaceutical, Inc. (company) — Registrant
FAQ
What is the nature of the material definitive agreement entered into by Collegium Pharmaceutical, Inc.?
The filing states that Collegium Pharmaceutical, Inc. entered into a material definitive agreement on April 26, 2024, but does not provide specific details about the agreement's nature.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the name of the counterparty to the material definitive agreement.
What is the effective date of this material definitive agreement?
The earliest event reported, which is the entry into the material definitive agreement, is dated April 26, 2024.
Are there any financial terms disclosed for this agreement?
No specific financial terms or dollar amounts related to the material definitive agreement are disclosed in this filing.
What is the primary business of Collegium Pharmaceutical, Inc.?
Collegium Pharmaceutical, Inc. is in the business of Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
Filing Stats: 771 words · 3 min read · ~3 pages · Grade level 14.3 · Accepted 2024-04-29 08:05:30
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share COLL The NASDAQ Global Sele
Filing Documents
- tm2412857d1_8k.htm (8-K) — 23KB
- 0001104659-24-053506.txt ( ) — 193KB
- coll-20240426.xsd (EX-101.SCH) — 3KB
- coll-20240426_lab.xml (EX-101.LAB) — 33KB
- coll-20240426_pre.xml (EX-101.PRE) — 22KB
- tm2412857d1_8k_htm.xml (XML) — 4KB
01
Item 1.01 Entry Into a Material Definitive Agreement. On April 26, 2024, Collegium Pharmaceutical, Inc. (the "Company") entered into an Authorized Generic Agreement (the "AG Agreement") with Hikma Pharmaceuticals USA Inc. ("Hikma"), pursuant to which the Company granted to Hikma certain rights relating to an authorized generic version of the Company's Nucynta IR product (the "Nucynta IR Authorized Generic") and the Company's Nucynta ER product (the "Nucynta ER Authorized Generic" and, collectively, the "Nucynta AG Products") in the United States. Under the terms of the AG Agreement, the Company granted Hikma the exclusive right to market the Nucynta AG Products in the United States. Hikma agreed to launch the Nucynta IR Authorized Generic and the Nucynta ER Authorized Generic 30 days prior to loss of exclusivity for each product or earlier under certain circumstances as set forth in the AG Agreement. Hikma will pay the Company a percentage of Net Profits (as defined in the AG Agreement) on sales of the Nucynta AG Products, with the Company's profit share percentage beginning in the mid-80% range, and declining based on the number of third-party generic equivalents sold for each Nucynta AG Product, if any. During the term of the AG Agreement, the Company will supply Hikma with its requirements of the Nucynta AG Products at Collegium's fully burdened manufacturing cost and Hikma will purchase the Nucynta AG Products exclusively from the Company. In addition, Hikma agreed that it will not market any generic equivalent of Nucynta IR or Nucynta ER at the same time it is marketing the Nucynta AG Products. The AG Agreement has an initial term of five years, with automatic one-year renewals unless notice of termination is provided by either party prior to expiration. The AG Agreement may be terminated by either party in the event of uncured material breach by the other party or certain bankruptcy or insolvency events experienced by the other party. In addition, if Hikm
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 29, 2024 Collegium Pharmaceutical, Inc. By: /s/ Colleen Tupper Name: Colleen Tupper Title: Executive Vice President and Chief Financial Officer